Arcus Biosciences Inc
RCUS20.250USD
+0.790+4.06%
收盤 11/11, 16:00（美東）報價延遲15分鐘
2.17B總市值
虧損本益比TTM
關於 Arcus Biosciences Inc 公司
Arcus Biosciences, Inc. 是一家臨牀階段生物製藥公司，致力於爲癌症患者開發差異化分子和聯合療法。該公司涉及一系列研究產品，這些產品正處於臨牀開發階段，其先進分子是一種針對肺癌和胃腸道癌症的抗 TIGIT 抗體。該公司有大約七個臨牀項目，重點關注靶點，包括 TIGIT、PD-1、腺苷 A2a 和 A2b 受體、CD73、CD39、HIF-2a 和 AXL。該公司正在共同開發四種研究產品，包括 zimberelimab（Arcuss 抗 PD-1 分子）、domvanalimab（Arcuss 抗 TIGIT 抗體）、etrumadenant（Arcuss 腺苷受體拮抗劑）和 quemliclustat（Arcuss CD73 抑制劑）。該公司正致力於開展 domvanalimab 與抗 PD-1 抗體 zimberelimab 聯合治療的 II 期和 III 期開發計劃，用於治療肺癌和胃腸癌等多種疾病。
Arcus Biosciences Inc簡介
公司代碼RCUS
公司名稱Arcus Biosciences Inc
上市日期Mar 15, 2018
CEODr. Terry J. Rosen, Ph.D.
員工數量627
證券類型Ordinary Share
年結日Mar 15
公司地址3928 Point Eden Way
城市HAYWARD
上市交易所NYSE Consolidated
國家United States of America
郵編94545-3719
電話15106946200
網址https://arcusbio.com/
公司代碼RCUS
上市日期Mar 15, 2018
CEODr. Terry J. Rosen, Ph.D.
Arcus Biosciences Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
Dr. Andrew Perlman, M.D., Ph.D.
Dr. Andrew Perlman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard Markus, M.D., Ph.D.
Mr. Richard Markus, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kathryn E. Falberg
Ms. Kathryn E. Falberg
Independent Director
Independent Director
--
--
Ms. Jennifer A. Jarrett
Ms. Jennifer A. Jarrett
Chief Operating Officer
Chief Operating Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
業務USD
名稱
營收
佔比
License and development services revenue
152.00M
95.00%
Collaboration revenue
8.00M
5.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
License and development services revenue
152.00M
95.00%
Collaboration revenue
8.00M
5.00%
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Gilead Sciences Inc
23.01%
BlackRock Institutional Trust Company, N.A.
7.39%
The Vanguard Group, Inc.
4.85%
Point72 Asset Management, L.P.
4.37%
Woodline Partners LP
2.93%
其他
57.45%
持股股東
持股股東
佔比
Gilead Sciences Inc
23.01%
BlackRock Institutional Trust Company, N.A.
7.39%
The Vanguard Group, Inc.
4.85%
Point72 Asset Management, L.P.
4.37%
Woodline Partners LP
2.93%
其他
57.45%
股東類型
持股股東
佔比
Corporation
23.01%
Investment Advisor
21.31%
Hedge Fund
15.84%
Investment Advisor/Hedge Fund
10.10%
Individual Investor
4.15%
Research Firm
2.26%
Venture Capital
1.87%
Pension Fund
0.50%
Bank and Trust
0.23%
其他
20.73%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
427
71.30M
52.26%
-5.17M
2025Q2
441
104.25M
98.12%
+5.20M
2025Q1
461
106.23M
100.41%
+7.59M
2024Q4
458
92.45M
92.67%
-8.14M
2024Q3
459
92.17M
107.84%
+6.16M
2024Q2
456
90.82M
107.03%
+3.48M
2024Q1
456
91.60M
108.07%
-2.14M
2023Q4
455
76.21M
102.30%
-15.07M
2023Q3
450
76.35M
103.06%
-17.88M
2023Q2
441
78.29M
107.10%
-16.66M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Gilead Sciences Inc
31.42M
29.53%
--
--
Jul 13, 2025
BlackRock Institutional Trust Company, N.A.
10.09M
9.48%
+407.08K
+4.20%
Jun 30, 2025
The Vanguard Group, Inc.
6.54M
6.15%
-131.56K
-1.97%
Jun 30, 2025
Point72 Asset Management, L.P.
5.97M
5.61%
+3.10M
+108.11%
Jun 30, 2025
Woodline Partners LP
4.00M
3.76%
-1.13M
-21.99%
Jun 30, 2025
Suvretta Capital Management, LLC
3.69M
3.47%
+1.13M
+44.05%
Jun 30, 2025
State Street Investment Management (US)
3.63M
3.41%
-65.66K
-1.78%
Jun 30, 2025
Rosen Terry Jay
2.57M
2.42%
-472.90K
-15.53%
Mar 01, 2025
Fidelity Management & Research Company LLC
2.27M
2.13%
-1.86M
-45.07%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.66M
1.56%
-62.20K
-3.61%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
1.96%
Virtus LifeSci Biotech Clinical Trials ETF
1.05%
ALPS Medical Breakthroughs ETF
0.88%
Invesco S&P SmallCap Health Care ETF
0.6%
Tema Oncology ETF
0.52%
Invesco S&P SmallCap 600 Pure Growth ETF
0.47%
SPDR S&P Biotech ETF
0.24%
iShares Health Innovation Active ETF
0.23%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.13%
SPDR S&P 600 Small Cap Growth ETF
0.13%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比1.96%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.05%
ALPS Medical Breakthroughs ETF
佔比0.88%
Invesco S&P SmallCap Health Care ETF
佔比0.6%
Tema Oncology ETF
佔比0.52%
Invesco S&P SmallCap 600 Pure Growth ETF
佔比0.47%
SPDR S&P Biotech ETF
佔比0.24%
iShares Health Innovation Active ETF
佔比0.23%
Vanguard S&P Small-Cap 600 Growth Index Fund
佔比0.13%
SPDR S&P 600 Small Cap Growth ETF
佔比0.13%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
